Vita 34 presents itself in new size for the first time at the Annual General Meeting 2021

- High level of approval from shareholders for accelerated growth course
- New enlarged Supervisory Board presented and elected with large majority
- Resolutions to enable capital raising support planned product launches and further completion of European market consolidation

Leipzig / Berlin, 15 December 2021 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), Europe's leading cell bank, today presented itself to its shareholders in a new size for the first time following the completion of the business combination with PBKM at its Annual General Meeting 2021 held in Berlin. At the meeting, which was again held virtually, 58.3 percent of the voting capital was represented at the time of the vote.

During his presentation, the company's CEO, Dr. Wolfgang Knirsch, once again emphasized the enormous importance and opportunities arising from the company merger. "As by far the largest cell bank in Europe and the world's No. 3, we now more than ever have the financial, human and technological resources to be a leading provider in personalized medicine in every European market in the future," explained Dr. Wolfgang Knirsch. "Our exceedingly large customer base provides us with stable recurring revenues that comfortably underpin our accelerated growth path."

In addition to the usual resolutions on the appropriation of the balance sheet profit, the discharge of the Management Board and Supervisory Board and the election of the auditor, the enlargement of the Supervisory Board and its elections were also put to the vote. Furthermore, the compensation system for the members of the Management Board, the creation of new Authorized Capital 2021 and Conditional Capital 2021, and amendments to the Articles of Association were voted on.

In detail, the agenda items were voted on with the following percentage approval of voting shares:
Agenda item 2:    99.7 %
Agenda item 3:    99.5 %
Agenda item 4 a:    87.5 %
Agenda item 4 b:    99.3 %
Agenda item 4 c:    99.3 %
Agenda item 4 d:    99.3 %
Agenda item 4 e:    99.5 %
Agenda item 4 f:    99.3 %
Agenda item 5:    100.0 %
Agenda item 6:    99.6 %
Agenda item 7 a:    97.8 %
Agenda item 7 b:    98.0 %
Agenda item 7 c:    98.0 %
Agenda item 7 d:    97.7 %
Agenda item 7 e:    98.0 %
Agenda item 8:    97.8 %
Agenda item 9:    99.6 %
Agenda item 10:    99.2 %
Agenda item 11:    97.8 %
Agenda item 12:    99.9 %
Agenda item 13:    99.9 %
Agenda item 14:    99.7 %
Agenda item 15:    99.6 %
Agenda item 16:    100.0%

Further details on the agenda items voted on are available for download on the website of Vita 34 AG at https://ir.vita34.de/investor-relations/hauptversammlung/hauptversammlung-2021/.

Contact:
Ingo Middelmenne
Investor Relations
Vita 34 AG
Phone: +49 (0341) 48792 - 0
Mobile: +49 (0174) 9091190
Email: ingo.middelmenne@vita34.de

Company Profile
Vita 34 was founded in Leipzig in 1997 and, following the business combination with PBKM at the end of 2021, is now the leading cell bank in Europe. As Europe's first private cord blood bank and a pioneer in cell banking, the company is a full-service cryopreservation provider offering collection logistics, processing and storage of stem cells from umbilical cord blood and tissue. Based on the expansion of its business model in 2019, Vita 34 also intends to store adult body fat and the stem cells it contains, as well as immune cells from peripheral blood and the development of immune cell therapies in the future. The body's own cells are a valuable starting material for medical cell therapy and are kept alive at temperatures around minus 200 degrees Celsius so that they can be used as part of a treatment if required. More than 850,000 customers from more than 20 countries have already provided for their family's health with a cell depot at Vita 34.